A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
- EligibilityCriteria: Key Inclusion Criteria:  Participants must meet all of the following inclusion criteria:  Primary diagnosis of recurrent MDD or persistent MDD. Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s). Participants must be willing and able to comply with all study procedures and restrictions.  Key Exclusion Criteria:  Participants will be excluded from the study if they meet any of the following criteria:  Participant is pregnant or breastfeeding or plan to become pregnant during the study. Participant has an unstable medical condition or unstable chronic disease. Participant has a history of neurological abnormalities. Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD. Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy. Participant has an alcohol or substance use disorder.  Note: Other inclusion/exclusion criteria may apply - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult